Cap Vorinostat Unk


Indications and Reactions:

Role Indications Reactions
Primary
Acute Myeloid Leukaemia 45.5%
Multiple Myeloma 15.4%
Myelodysplastic Syndrome 7.2%
Mantle Cell Lymphoma 3.5%
Chronic Lymphocytic Leukaemia 3.2%
Oesophageal Adenocarcinoma 2.7%
Non-hodgkin's Lymphoma 2.4%
B-cell Lymphoma 2.1%
Breast Cancer 2.1%
Diffuse Large B-cell Lymphoma 2.1%
Glioblastoma Multiforme 2.1%
Neuroblastoma 2.1%
Hodgkin's Disease 1.6%
Non-hodgkin's Lymphoma Recurrent 1.6%
Ovarian Cancer 1.3%
Neoplasm Malignant 1.1%
Non-small Cell Lung Cancer 1.1%
Prophylaxis 1.1%
Renal Cell Carcinoma 1.1%
Gastric Cancer 0.8%
Vomiting 20.9%
White Blood Cell Count Decreased 13.0%
Thrombocytopenia 8.7%
Weight Decreased 7.0%
Pyrexia 4.3%
Renal Failure Acute 4.3%
Rhinorrhoea 4.3%
Urinary Retention 4.3%
Ventricular Extrasystoles 4.3%
Lobar Pneumonia 3.5%
Pleural Effusion 3.5%
Diarrhoea 2.6%
Neuropathy Peripheral 2.6%
Platelet Count Decreased 2.6%
Troponin Increased 2.6%
Urine Output Decreased 2.6%
Viral Infection 2.6%
White Blood Cell Count Increased 2.6%
Alanine Aminotransferase Increased 1.7%
Brain Herniation 1.7%
Secondary
Medulloblastoma 30.8%
Glioblastoma Multiforme 19.2%
Non-small Cell Lung Cancer 17.3%
Acute Myeloid Leukaemia 15.4%
Product Used For Unknown Indication 11.5%
Myelodysplastic Syndrome 3.8%
Drug Use For Unknown Indication 1.9%
Skin Ulcer 17.6%
Lung Infection 11.8%
Thrombocytopenia 11.8%
Urinary Tract Infection 11.8%
Diverticulitis 5.9%
Dysphagia 5.9%
Febrile Neutropenia 5.9%
Hydrocephalus 5.9%
Hypersensitivity 5.9%
Platelet Count Decreased 5.9%
White Blood Cell Count Decreased 5.9%
Wound Infection 5.9%

Drug Data